NEO— NEOGENOMICS INC

Health Care$2.1B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
NET REVENUE	$727.3M+10.1%	$660.6M+11.6%	$591.6M+16.1%	$509.7M
COST OF REVENUE	$413.0M+11.5%	$370.5M+6.8%	$347.0M+7.8%	$321.8M
GROSS MARGIN	$314.3M+8.3%	$290.1M+18.6%	$244.6M+30.2%	$187.9M
General and administrative	$273.3M+5.2%	$259.7M+6.8%	$243.1M-0.1%	$243.4M
Research and development	$37.1M+19.0%	$31.2M+14.1%	$27.3M-9.9%	$30.3M
Sales and marketing	$92.0M+8.7%	$84.7M+19.5%	$70.8M+5.2%	$67.3M
Restructuring charges	$0-100.0%	$6.7M-40.0%	$11.1M+145.5%	$4.5M
Impairment charges (Note 3 and Note 7)	$27.8M	$0	$0	—
Total operating expenses	$430.2M+12.6%	$382.2M+8.5%	$352.3M+2.0%	$345.5M
LOSS FROM OPERATIONS	-$115.9M-25.8%	-$92.1M+14.5%	-$107.7M+31.6%	-$157.6M
Interest income	-$9.1M+50.8%	-$18.4M-9.0%	-$16.9M-178.2%	-$6.1M
Interest expense	$3.8M-43.3%	$6.6M-4.2%	$6.9M-8.9%	$7.6M
Other (income) expense, net	-$296K-178.1%	$379K+158.9%	-$644K-402.3%	$213K
Loss before taxes	-$110.3M-36.7%	-$80.7M+16.9%	-$97.1M+39.1%	-$159.3M
Income tax benefit	-$2.2M-15.1%	-$1.9M+78.7%	-$9.1M+39.5%	-$15.1M
NET LOSS	-$108.0M-37.2%	-$78.7M+10.5%	-$88.0M+39.0%	-$144.3M
Basic (in dollars per share)	-$840.00-35.5%	-$620.00+11.4%	-$700.00+39.7%	-$1160.00
Diluted (in dollars per share)	-$840.00-35.5%	-$620.00+11.4%	-$700.00+39.7%	-$1160.00
Basic (in shares)	128.1M+1.1%	126.7M+0.9%	125.5M+1.0%	124.2M
Diluted (in shares)	128.1M+1.1%	126.7M+0.9%	125.5M+1.0%	124.2M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.